The relative lack of GPER signaling, particularly in biological males and postmenopausal women, has been implicated in various diseases, including cancer, metabolic disorders, and cardiovascular disease, making GPER a target for agonist drug development (1, 2). This evidence concerns the gene GPER1 and Other metabolic disease.